Φορτώνει......
Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: A pharmacovigilance study
BACKGROUND. Immune-checkpoint-inhibitors (ICIs) have dramatically improved clinical outcomes in multiple cancer types and are increasingly being used in early disease settings and in combinations. However, ICIs can also cause severe or even fatal immune-mediated adverse-events (irAE). Here, we ident...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Lancet Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6287923/ https://ncbi.nlm.nih.gov/pubmed/30442497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30608-9 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|